Loading
Memphis paediatric neuro-oncologist who led the study showing that the Hedgehog inhibitor vismodegib helps only adults and older children whose medulloblastoma belongs to the SHH subgroup, an early example of subgroup-directed brain tumour therapy.
Giles Robinson is a paediatric neuro-oncologist at St. Jude Children's Research Hospital and leads its medulloblastoma programme, including the SJMB12 trial that treats patients according to molecular subgroup. He was first author of the 2015 Journal of Clinical Oncology report of the vismodegib trials in recurrent medulloblastoma, which showed responses were confined to SHH-subgroup tumours with upstream pathway mutations and that the drug caused growth-plate fusion in growing children.
| Title | Journal | Year |
|---|---|---|
| Vismodegib in recurrent sonic hedgehog-subgroup medulloblastoma (PBTC-025B and PBTC-032) | Journal of Clinical Oncology | 2015 |
Shares Childhood cancers (all types) and the tags paediatric, brain, targeted-therapy, trialist.
Shares Medulloblastoma, Childhood cancers (all types) and the tags paediatric, brain, trialist.
Shares Childhood cancers (all types) and the tags paediatric, brain, trialist.
Shares St. Jude Children's Research Hospital, Medulloblastoma and the tag paediatric.
Shares Childhood cancers (all types) and the tags paediatric, trialist.
Shares Childhood cancers (all types) and the tags paediatric, trialist.
Shares the tags brain, trialist.
Shares the tags brain, trialist.